Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin

被引：17

作者：

Growcott, E. J. ^{[1
]}

Coulthard, A. ^{[1
]}

Amison, R. ^{[1
]}

Hardaker, E. L. ^{[1
]}

Saxena, V. ^{[2
]}

Malt, L. ^{[2
]}

Jones, P. ^{[1
]}

Grevot, A. ^{[3
]}

Poll, C. ^{[1
]}

Osborne, C. ^{[2
]}

Banner, K. H. ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Horsham RH12 5AB, W Sussex, England

[2] Novartis Inst Biomed Res, Cambridge, MA 02139 USA

[3] Novartis Pharma AG, CH-4057 Basel, Switzerland

来源：

JOURNAL OF CYSTIC FIBROSIS | 2011年 / 10卷 / 03期

关键词：

Pseudomonas aeruginosa; Agar beads; Ciprofloxacin; SUPPRESSES BACTERIAL PROLIFERATION; CYSTIC-FIBROSIS MICE; LUNG INFECTION; INFLAMMATION; PNEUMONIA; THERAPY;

D O I：

10.1016/j.jcf.2010.12.007

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: We sought to characterise a refined rat model of respiratory infection with P. aeruginosa over an acute time course and test the antibiotic ciprofloxacin. Methods: Agar beads were prepared +/- SPAN (R) 80. Rats were inoculated with sterile agar beads or those containing 10(5) colony forming units (cfu) P. aeruginosa via intra-tracheal dosing. Bacterial load and inflammatory parameters were measured. Results: Differing concentrations of SPAN (R) 80 modified median agar bead diameter and reduced particle size distribution. Beads prepared with 0.01% v/v SPAN (R) 80 were evaluated in vivo. A stable lung infection up to 7 days post infection was achieved and induced BALF neutrophilia 2 and 5 days post infection. Ciprofloxacin (50 mg/kg) significantly attenuated infection without affecting the inflammatory parameters measured. Conclusion: SPAN (R) 80 can control the particle size and lung distribution of agar beads and P. aeruginosa-embedded beads prepared with 0.01%v/v SPAN (R) 80 can induce infection and inflammation over 7 days. (C) 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

引用

页码：166 / 174

页数：9

共 21 条

[1] Role of cytokine-induced neutrophil chemoattractant-2 (cinc-2) α in a rat model of chronic bronchopulmonary infections with Pseudomonas aeruginosa [J].

Amano, H ;

Oishi, K ;

Sonoda, F ;

Senba, M ;

Wada, A ;

Nakagawa, H ;

Nagatake, T .

CYTOKINE, 2000, 12 (11) :1662-1668

[2] INFLAMMATORY CYTOKINES IN CYSTIC-FIBROSIS LUNGS [J].

BONFIELD, TL ;

PANUSKA, JR ;

KONSTAN, MW ;

HILLIARD, KA ;

HILLIARD, JB ;

GHNAIM, H ;

BERGER, M .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (06) :2111-2118

[3] Chronic pneumonia with Pseudomonas aeruginosa and impaired alveolar fluid clearance -: art. no. 17 [J].

Boyer, S ;

Faure, K ;

Ader, F ;

Husson, MO ;

Kipnis, E ;

Prangere, T ;

Leroy, X ;

Guery, BP .

RESPIRATORY RESEARCH, 2005, 6 (17)

[4] Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection [J].

Cantin, AM ;

Woods, DE .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (04) :1130-1135

[5]

CASH HA, 1979, AM REV RESPIR DIS, V119, P453

[6]

Courtney J M, 2004, J Cyst Fibros, V3, P223, DOI 10.1016/j.jcf.2004.06.006

[7] Immunomodulatory effects of quinolones [J].

Dalhoff, A ;

Shalit, L .

LANCET INFECTIOUS DISEASES, 2003, 3 (06) :359-371

[8] SUBINHIBITORY ANTIBIOTICS REDUCE PSEUDOMONAS-AERUGINOSA TISSUE-INJURY IN THE RAT LUNG MODEL [J].

GRIMWOOD, K ;

TO, M ;

RABIN, HR ;

WOODS, DE .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (06) :937-945

[9] Cystic fibrosis mouse models [J].

Guilbault, Claudine ;

Saeed, Zienab ;

Downey, Gregory P. ;

Radzioch, Danuta .

AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2007, 36 (01) :1-7

[10] Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience [J].

Hansen, C. R. ;

Pressler, T. ;

Hoiby, N. .

JOURNAL OF CYSTIC FIBROSIS, 2008, 7 (06) :523-530

← 1 2 3 →